Expertise in
23
conditions
Expertise in
23
conditions
University Of Michigan Medical Center
1500 E Medical Center Dr, 
Ann Arbor, MI 

Overview

Rajen Mody is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Mody is highly rated in 23 conditions, according to our data. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Infantile Neutropenia, Glioma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 118 peer reviewed articles and participating in 73 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Pediatrics in MI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Priority Health
  • HMO
  • POS

Locations

University of Michigan Medical Center
1500 E Medical Center Dr, Ann Arbor, MI 48109
Other Locations
Regents of the University of Michigan
3621 S State St, Ann Arbor, MI 48108

Additional Areas of Focus

Dr. Mody has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


72 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Neuroblastoma Biology Studies
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
View 48 Less Clinical Trials
Similar Doctors
Expertise in
31
conditions
Hematology | Oncology
Expertise in
31
conditions
Hematology | Oncology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (0.1 miles away)
Languages Spoken:
English

Kelly Walkovich is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Walkovich is highly rated in 31 conditions, according to our data. Her top areas of expertise are Hemophagocytic Lymphohistiocytosis, Infantile Neutropenia, Non-Langerhans-Cell Histiocytosis, and Reticulohistiocytoma.

Expertise in
5
conditions
Hematology | Oncology
Expertise in
5
conditions
Hematology | Oncology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (0.1 miles away)
Languages Spoken:
English

Steven Pipe is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Pipe is highly rated in 5 conditions, according to our data. His top areas of expertise are Hemophilia A, Hemophilia B, Blood Clots, and Von Willebrand Disease (VWD).

Expertise in
9
conditions
Hematology | Oncology
Expertise in
9
conditions
Hematology | Oncology

Office

1500 E Medical Center Dr Fl Rec, 
Ann Arbor, MI 
 (1.1 miles away)
Languages Spoken:
English

Gregory Yanik is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Yanik is highly rated in 9 conditions, according to our data. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Graft Versus Host Disease (GvHD), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Rajen Mody

How do I make an appointment with Dr. Rajen Mody?

You can book an appointment with Dr. Rajen Mody by calling their office at 734-936-9814. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rajen Mody a top-rated expert for Neuroblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rajen Mody is classified as an Elite expert for Neuroblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rajen Mody specialize in?

While Dr. Rajen Mody is a Hematology, they have specific expertise in Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Infantile Neutropenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Rajen Mody participate in research or clinical trials?

Yes. Dr. Rajen Mody has published 118 articles and abstracts on conditions like Neuroblastoma. You can view a list of Dr. Rajen Mody's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rajen Mody accept my insurance?

Dr. Rajen Mody accepts most major insurance plans, including Blue Cross Blue Shield and CareSource. We recommend calling the office directly at 734-936-9814 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mody's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile